Immunohistochemical profile and molecular markers of lung carcinoma in tertiary care medical center - A retrospective observational study
DOI:
https://doi.org/10.71152/ajms.v16i5.4481Keywords:
Lung carcinoma; Thyroid transcription factor-1; Cytokeratin 7; Epidermal growth factor receptor mutations; ImmunohistochemistryAbstract
Background: Lung carcinoma is one of the most prevalent malignancies globally, with high morbidity and mortality rates due to late-stage diagnosis and aggressive disease progression. Understanding immunohistochemical and molecular profiles is essential for improving diagnostic precision and guiding personalized therapy.
Aims and Objective: This study aimed to evaluate the immunohistochemical profiles and molecular markers of lung carcinoma at a tertiary care center.
Materials and Methods: This retrospective observational study included 67 patients diagnosed with lung carcinoma between June 2019 and June 2024. Data on patient demographics, histopathological subtypes, immunohistochemical markers (thyroid transcription factor-1 [TTF1], cytokeratin 7 [CK7], p63, and others), and molecular markers (epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], and ROS1) were analyzed. Statistical analyses were performed using SPSS v26.
Results: Non-small-cell lung carcinoma (NSCLC) adenocarcinoma was the predominant subtype (85.1%), followed by squamous cell carcinoma (11.9%). TTF1 and CK7 were positive in 82.1% and 40.3% of cases, respectively, whereas p63 was positive in 17.9%, primarily in squamous carcinoma. EGFR mutations were detected in 52.5% of cases, highlighting their therapeutic relevance. ALK and ROS1 rearrangements were absent in all the tested cases.
Conclusion: This study emphasizes the predominance of NSCLC adenocarcinoma and the diagnostic importance of TTF1 and CK7 expression. Molecular profiling is critical for the effective management of lung cancer with targeted therapies.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
